No more injections? The new pill could replace Ozempic and Wogovy to lose weight

An oral pill for weight loss has had a good performance in clinical trials, positioning it as a potential alternative to GLP-1 medications such as Ozempic and Wogovy.

The Eli Lilly medicine, called Orforglipron, demonstrated “significant weight loss” and cardiomethabolic improvements, according to a press release.

Phase 3 test, which was published in the New England Journal of Medicine, evaluated the safety and effectiveness of the medication in adults that have a medical problem related to weight and have no diabetes.

Drugs to lose weight could add years to the lives of Americans, researchers project

Participants underwent 72 weeks of treatment with three different doses (6 mg, 12 mg and 36 mg).

After the trial period, the results showed that Orforglipron complied with the “primary end point of the upper reduction of body weight” compared to a placebo.

Those who took the highest dose lost an average of 27.3 pounds. Almost 60% of these participants lost 10% of their body weight, while 39.6% lost at least 15%.

Of the 1,127 participants who had pre-diabetes at the beginning of the study, up to 91% achieved almost normal blood sugar levels compared to the 42% that a placebo took, the researchers found.

Orforglipron showed “clinically significant improvements” in cardiovascular risk factors associated with obesity, such as non -HDL cholesterol, systolic blood pressure and triglycerides.

Popular weight loss medication could relieve painful arthritis symptoms, doctors report

The highest dose also reduced a marker for inflammation, called high sensitivity C -reactive protein, in 47.7%.

The study found that the medicine security profile is consistent with existing LPG-1 medications. The most common side effects were gastrointestinal, including nausea, constipation, diarrhea and vomiting, mild to moderate gravity.

Sean Wharton, MD, director of Wharton Medical Clinic and main author of the study in Canada, wrote in a statement that obesity is a “global and complex health challenge” that requires treatment options that are “effective and easy to integrate into everyday life.”

‘Next Ozempic’ aims to offer a weight loss of 30% with less side effects

“In this phase 3 study, Orforglipron demonstrated strong efficiency and security results consisting of the GLP-1 class, reinforcing its potential as a first-line treatment in primary care,” he said in the press release.

“Orforglipron could help reduce known cardiovascular risk markers associated with obesity and support significant improvements in public health.”

Lilly announced that he advances with plans to obtain the approval of orforgripron as a drug of obesity. The company hopes that the green light can already obtain in 2026. In the same year, it also plans to request approval to use the medicine for the treatment of type 2 diabetes.

Reuters reported that this pill could be “accelerated” under a review process of one to two months launched by the Food and Medicines Administration, according to Wall Street analysts.

Click here to get the News application

“Analysts speculate that the medicine, offorgripron, is a viable candidate given the growing load of costly injectable medications to lose weight and the fact that Lilly is expanding its American manufacture, problems that the Trump administration has prioritized,” Reuters wrote.

Click here to register in our health newsletter

In an interview with News Digital, Sue Decotiis, MD, medical weight loss in New York City, described this drug as a “positive addition to the arms” that is cheaper to produce and less expensive for the consumer.

However, Deciis said that the results of “not as impressive” weight loss as the results of injectables such as Ozempic and Mounjaro.

“However, compliance with Orforglipron can be better, since it is an oral medication and not an injectable,” he said.

A concern with this new drug, according to Decotiis, is that it is not a peptide, which has a high safety factor and is “easy for the body to metabolize and adjust.”

For more health articles, visit www.Newsnews.com/health

“There could be unknown consequences in the long term that we have not yet known,” he added. “I think there will be more drugs of oral weight loss in the pipe and I hope they are in the peptide category.”

News Digital contacted Eli Lilly to comment.